Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23799922 | 0.84 | NR1H2 (0.37) | ALDH1A1XDHMAPK1 | |
| SCHEMBL31300761 | 0.83 | XDH (0.47) | ALDH1A1XDHL3MBTL1KDM4EGAA | |
| SCHEMBL23800453 | 0.72 | IGF1R (0.35) | ALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL20605116 | 0.70 | ALDH1A1 (0.38) | ALDH1A1MAPK1KDM4EGAAMAPT | |
| SCHEMBL20604800 | 0.68 | TSHR (0.39) | ALDH1A1KDM4EGAA | |
| SCHEMBL23799465 | 0.68 | XDH (0.42) | XDHL3MBTL1MAPT | |
| SCHEMBL20605084 | 0.66 | XDH (0.49) | ALDH1A1XDHL3MBTL1KDM4EGAA | |
| SCHEMBL2511971 | 0.65 | PTPN1 (0.45) | ALDH1A1XDHMAPK1L3MBTL1KDM4E | |
| SCHEMBL25427831 | 0.65 | MAPT (0.34) | XDHKDM4EMAPT | |
| SCHEMBL30462942 | 0.65 | MAPT (0.34) | XDHKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | ALDH1A1 2556/4885XDH 3349/4885MAPK1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.